Prognostic value of geriatric and cardiac parameters for one-year mortality in older heart failure patients. A

L Kestens1, S Billet1, L Hens2

  • 1Department of Geriatric Medicine, Ghent University Hospital, Ghent, Belgium.

PubMed

Insights

Older heart failure patients with lower blood pressure and more severe comorbidities face higher one-year mortality risk. Functional status and geriatric risk profiles did not predict survival in this high-risk group.

Area of Science:

  • Geriatric Medicine
  • Cardiology
  • Internal Medicine

Background:

  • Heart failure (HF) is a prevalent condition in the elderly population, often associated with a poor prognosis.
  • Identifying older HF patients at high risk for mortality is crucial for effective clinical management and resource allocation.

Purpose of the Study:

  • To identify prognostic, geriatric, and cardiac parameters that can predict one-year mortality in older patients hospitalized with heart failure.
  • To differentiate between factors influencing survival in elderly individuals with HF.

Main Methods:

  • A multicentre, observational cohort study involving 147 heart failure patients aged 75 years and older.
  • Patients were recruited from cardiac or geriatric departments of two hospitals.
  • One-year survival was the primary outcome measure, analyzed using univariate (Chi-square, T-test) and multivariate (Logistic, Cox regression) methods.

Main Results:

  • The one-year mortality rate was 28% (41/147).
  • Non-survivors exhibited significantly lower systolic blood pressure at discharge (125.26 mmHg vs. 137.59 mmHg) and more severe comorbidities (age-adjusted Charlson Comorbidity Index: 8.80 vs. 7.40) compared to survivors.
  • Decreasing systolic blood pressure and increasing Charlson Comorbidity Index were significant predictors of mortality (Logistic and Cox regression analyses).

Conclusions:

  • Lower systolic blood pressure at discharge and a higher comorbidity burden are independently associated with increased one-year mortality in older, hospitalized heart failure patients.
  • Patient functionality and the presence of a geriatric risk profile were not significantly related to one-year mortality in this cohort.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
141
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
80
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K